Anaphylaxis post-COVID 19 vaccinations in Singapore
Peck et al discuss their study on anaphylaxis post-COVID 19 vaccinations in Singapore. Anaphylaxis was the first serious adverse event (AE) of special interest following COVID-19 vaccination to have surfaced in Singapore. Locally, individuals who developed physician-diagnosed anaphylaxis or severe a...
Gespeichert in:
| Veröffentlicht in: | Drug safety 2023-11, Vol.46 (11), p.1212-1214 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1214 |
|---|---|
| container_issue | 11 |
| container_start_page | 1212 |
| container_title | Drug safety |
| container_volume | 46 |
| creator | Peck, L F Teo, D Poh, W W Theen, A L Soh, S B L Tham, M Y Foo, B P Q Jing, A N Jing NG, P S Ling Ang, P S Chan, C L Toh, D S L Lee, E J D Santosa, A Thong, B Y H Bever, H V Lee, H Y Sum, C F Dorajoo, S R |
| description | Peck et al discuss their study on anaphylaxis post-COVID 19 vaccinations in Singapore. Anaphylaxis was the first serious adverse event (AE) of special interest following COVID-19 vaccination to have surfaced in Singapore. Locally, individuals who developed physician-diagnosed anaphylaxis or severe allergic reactions to the mRNA vaccines would be medically ineligible for mRNA vaccines and offered non-mRNA vaccines as alternatives. Hence, patients who received heterologous vaccination were expected to largely comprise such at risk individuals and it will be of interest to review these patients further. The results revealed that anaphylaxis is a rare but serious AE following COVID-19 vaccination. The outcomes of anaphylaxis can be mitigated with timely medical intervention. The review of the anaphylaxis cases helped to guide vaccination strategies and adds to the cumulative knowledge of heterologous vaccination, in particular in persons with multiple allergies. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_2890077151</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2890077151</sourcerecordid><originalsourceid>FETCH-proquest_journals_28900771513</originalsourceid><addsrcrecordid>eNpjYuA0NDS31DW0NDFiYeA0MDQ00TW1NDTjYOAqLs4yMDCwMDKz4GQwdsxLLMiozEmsyCxWKMgvLtF19g_zdFEwtFQoS0xOzsxLLMnMzytWyMxTCM7MS08syC9K5WFgTUvMKU7lhdLcDMpuriHOHroFRfmFpanFJfFZ-aVFeUCpeCMLSwMDc3NDU0Nj4lQBAKWpNMI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2890077151</pqid></control><display><type>article</type><title>Anaphylaxis post-COVID 19 vaccinations in Singapore</title><source>SpringerLink Journals</source><creator>Peck, L F ; Teo, D ; Poh, W W ; Theen, A L ; Soh, S B L ; Tham, M Y ; Foo, B P Q ; Jing, A N Jing ; NG, P S Ling ; Ang, P S ; Chan, C L ; Toh, D S L ; Lee, E J D ; Santosa, A ; Thong, B Y H ; Bever, H V ; Lee, H Y ; Sum, C F ; Dorajoo, S R</creator><creatorcontrib>Peck, L F ; Teo, D ; Poh, W W ; Theen, A L ; Soh, S B L ; Tham, M Y ; Foo, B P Q ; Jing, A N Jing ; NG, P S Ling ; Ang, P S ; Chan, C L ; Toh, D S L ; Lee, E J D ; Santosa, A ; Thong, B Y H ; Bever, H V ; Lee, H Y ; Sum, C F ; Dorajoo, S R</creatorcontrib><description>Peck et al discuss their study on anaphylaxis post-COVID 19 vaccinations in Singapore. Anaphylaxis was the first serious adverse event (AE) of special interest following COVID-19 vaccination to have surfaced in Singapore. Locally, individuals who developed physician-diagnosed anaphylaxis or severe allergic reactions to the mRNA vaccines would be medically ineligible for mRNA vaccines and offered non-mRNA vaccines as alternatives. Hence, patients who received heterologous vaccination were expected to largely comprise such at risk individuals and it will be of interest to review these patients further. The results revealed that anaphylaxis is a rare but serious AE following COVID-19 vaccination. The outcomes of anaphylaxis can be mitigated with timely medical intervention. The review of the anaphylaxis cases helped to guide vaccination strategies and adds to the cumulative knowledge of heterologous vaccination, in particular in persons with multiple allergies.</description><identifier>ISSN: 0114-5916</identifier><identifier>EISSN: 1179-1942</identifier><language>eng</language><publisher>Auckland: Springer Nature B.V</publisher><subject>Allergic reactions ; Allergies ; Anaphylaxis ; Collaboration ; COVID-19 ; COVID-19 vaccines ; Immunization ; mRNA ; mRNA vaccines ; Patient safety ; Patients ; Public health ; Severe acute respiratory syndrome coronavirus 2 ; Vaccines</subject><ispartof>Drug safety, 2023-11, Vol.46 (11), p.1212-1214</ispartof><rights>Copyright Springer Nature B.V. Nov 2023</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids></links><search><creatorcontrib>Peck, L F</creatorcontrib><creatorcontrib>Teo, D</creatorcontrib><creatorcontrib>Poh, W W</creatorcontrib><creatorcontrib>Theen, A L</creatorcontrib><creatorcontrib>Soh, S B L</creatorcontrib><creatorcontrib>Tham, M Y</creatorcontrib><creatorcontrib>Foo, B P Q</creatorcontrib><creatorcontrib>Jing, A N Jing</creatorcontrib><creatorcontrib>NG, P S Ling</creatorcontrib><creatorcontrib>Ang, P S</creatorcontrib><creatorcontrib>Chan, C L</creatorcontrib><creatorcontrib>Toh, D S L</creatorcontrib><creatorcontrib>Lee, E J D</creatorcontrib><creatorcontrib>Santosa, A</creatorcontrib><creatorcontrib>Thong, B Y H</creatorcontrib><creatorcontrib>Bever, H V</creatorcontrib><creatorcontrib>Lee, H Y</creatorcontrib><creatorcontrib>Sum, C F</creatorcontrib><creatorcontrib>Dorajoo, S R</creatorcontrib><title>Anaphylaxis post-COVID 19 vaccinations in Singapore</title><title>Drug safety</title><description>Peck et al discuss their study on anaphylaxis post-COVID 19 vaccinations in Singapore. Anaphylaxis was the first serious adverse event (AE) of special interest following COVID-19 vaccination to have surfaced in Singapore. Locally, individuals who developed physician-diagnosed anaphylaxis or severe allergic reactions to the mRNA vaccines would be medically ineligible for mRNA vaccines and offered non-mRNA vaccines as alternatives. Hence, patients who received heterologous vaccination were expected to largely comprise such at risk individuals and it will be of interest to review these patients further. The results revealed that anaphylaxis is a rare but serious AE following COVID-19 vaccination. The outcomes of anaphylaxis can be mitigated with timely medical intervention. The review of the anaphylaxis cases helped to guide vaccination strategies and adds to the cumulative knowledge of heterologous vaccination, in particular in persons with multiple allergies.</description><subject>Allergic reactions</subject><subject>Allergies</subject><subject>Anaphylaxis</subject><subject>Collaboration</subject><subject>COVID-19</subject><subject>COVID-19 vaccines</subject><subject>Immunization</subject><subject>mRNA</subject><subject>mRNA vaccines</subject><subject>Patient safety</subject><subject>Patients</subject><subject>Public health</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Vaccines</subject><issn>0114-5916</issn><issn>1179-1942</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNpjYuA0NDS31DW0NDFiYeA0MDQ00TW1NDTjYOAqLs4yMDCwMDKz4GQwdsxLLMiozEmsyCxWKMgvLtF19g_zdFEwtFQoS0xOzsxLLMnMzytWyMxTCM7MS08syC9K5WFgTUvMKU7lhdLcDMpuriHOHroFRfmFpanFJfFZ-aVFeUCpeCMLSwMDc3NDU0Nj4lQBAKWpNMI</recordid><startdate>20231101</startdate><enddate>20231101</enddate><creator>Peck, L F</creator><creator>Teo, D</creator><creator>Poh, W W</creator><creator>Theen, A L</creator><creator>Soh, S B L</creator><creator>Tham, M Y</creator><creator>Foo, B P Q</creator><creator>Jing, A N Jing</creator><creator>NG, P S Ling</creator><creator>Ang, P S</creator><creator>Chan, C L</creator><creator>Toh, D S L</creator><creator>Lee, E J D</creator><creator>Santosa, A</creator><creator>Thong, B Y H</creator><creator>Bever, H V</creator><creator>Lee, H Y</creator><creator>Sum, C F</creator><creator>Dorajoo, S R</creator><general>Springer Nature B.V</general><scope>3V.</scope><scope>4T-</scope><scope>7RV</scope><scope>7T2</scope><scope>7TK</scope><scope>7U7</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20231101</creationdate><title>Anaphylaxis post-COVID 19 vaccinations in Singapore</title><author>Peck, L F ; Teo, D ; Poh, W W ; Theen, A L ; Soh, S B L ; Tham, M Y ; Foo, B P Q ; Jing, A N Jing ; NG, P S Ling ; Ang, P S ; Chan, C L ; Toh, D S L ; Lee, E J D ; Santosa, A ; Thong, B Y H ; Bever, H V ; Lee, H Y ; Sum, C F ; Dorajoo, S R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_28900771513</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Allergic reactions</topic><topic>Allergies</topic><topic>Anaphylaxis</topic><topic>Collaboration</topic><topic>COVID-19</topic><topic>COVID-19 vaccines</topic><topic>Immunization</topic><topic>mRNA</topic><topic>mRNA vaccines</topic><topic>Patient safety</topic><topic>Patients</topic><topic>Public health</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Peck, L F</creatorcontrib><creatorcontrib>Teo, D</creatorcontrib><creatorcontrib>Poh, W W</creatorcontrib><creatorcontrib>Theen, A L</creatorcontrib><creatorcontrib>Soh, S B L</creatorcontrib><creatorcontrib>Tham, M Y</creatorcontrib><creatorcontrib>Foo, B P Q</creatorcontrib><creatorcontrib>Jing, A N Jing</creatorcontrib><creatorcontrib>NG, P S Ling</creatorcontrib><creatorcontrib>Ang, P S</creatorcontrib><creatorcontrib>Chan, C L</creatorcontrib><creatorcontrib>Toh, D S L</creatorcontrib><creatorcontrib>Lee, E J D</creatorcontrib><creatorcontrib>Santosa, A</creatorcontrib><creatorcontrib>Thong, B Y H</creatorcontrib><creatorcontrib>Bever, H V</creatorcontrib><creatorcontrib>Lee, H Y</creatorcontrib><creatorcontrib>Sum, C F</creatorcontrib><creatorcontrib>Dorajoo, S R</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Drug safety</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Peck, L F</au><au>Teo, D</au><au>Poh, W W</au><au>Theen, A L</au><au>Soh, S B L</au><au>Tham, M Y</au><au>Foo, B P Q</au><au>Jing, A N Jing</au><au>NG, P S Ling</au><au>Ang, P S</au><au>Chan, C L</au><au>Toh, D S L</au><au>Lee, E J D</au><au>Santosa, A</au><au>Thong, B Y H</au><au>Bever, H V</au><au>Lee, H Y</au><au>Sum, C F</au><au>Dorajoo, S R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anaphylaxis post-COVID 19 vaccinations in Singapore</atitle><jtitle>Drug safety</jtitle><date>2023-11-01</date><risdate>2023</risdate><volume>46</volume><issue>11</issue><spage>1212</spage><epage>1214</epage><pages>1212-1214</pages><issn>0114-5916</issn><eissn>1179-1942</eissn><abstract>Peck et al discuss their study on anaphylaxis post-COVID 19 vaccinations in Singapore. Anaphylaxis was the first serious adverse event (AE) of special interest following COVID-19 vaccination to have surfaced in Singapore. Locally, individuals who developed physician-diagnosed anaphylaxis or severe allergic reactions to the mRNA vaccines would be medically ineligible for mRNA vaccines and offered non-mRNA vaccines as alternatives. Hence, patients who received heterologous vaccination were expected to largely comprise such at risk individuals and it will be of interest to review these patients further. The results revealed that anaphylaxis is a rare but serious AE following COVID-19 vaccination. The outcomes of anaphylaxis can be mitigated with timely medical intervention. The review of the anaphylaxis cases helped to guide vaccination strategies and adds to the cumulative knowledge of heterologous vaccination, in particular in persons with multiple allergies.</abstract><cop>Auckland</cop><pub>Springer Nature B.V</pub></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0114-5916 |
| ispartof | Drug safety, 2023-11, Vol.46 (11), p.1212-1214 |
| issn | 0114-5916 1179-1942 |
| language | eng |
| recordid | cdi_proquest_journals_2890077151 |
| source | SpringerLink Journals |
| subjects | Allergic reactions Allergies Anaphylaxis Collaboration COVID-19 COVID-19 vaccines Immunization mRNA mRNA vaccines Patient safety Patients Public health Severe acute respiratory syndrome coronavirus 2 Vaccines |
| title | Anaphylaxis post-COVID 19 vaccinations in Singapore |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T03%3A51%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anaphylaxis%20post-COVID%2019%20vaccinations%20in%20Singapore&rft.jtitle=Drug%20safety&rft.au=Peck,%20L%20F&rft.date=2023-11-01&rft.volume=46&rft.issue=11&rft.spage=1212&rft.epage=1214&rft.pages=1212-1214&rft.issn=0114-5916&rft.eissn=1179-1942&rft_id=info:doi/&rft_dat=%3Cproquest%3E2890077151%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2890077151&rft_id=info:pmid/&rfr_iscdi=true |